200 related articles for article (PubMed ID: 19399690)
1. The late adverse events of rituximab therapy--rare but there!
Ram R; Ben-Bassat I; Shpilberg O; Polliack A; Raanani P
Leuk Lymphoma; 2009 Jul; 50(7):1083-95. PubMed ID: 19399690
[TBL] [Abstract][Full Text] [Related]
2. [Rituximab. A monoclonal CD20 antibody--hematological indications and possible treatments for immunoinflammatory diseases].
Hansen PB; Hasselbalch HC
Ugeskr Laeger; 2004 Feb; 166(6):466-9. PubMed ID: 15045710
[No Abstract] [Full Text] [Related]
3. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
Wolach O; Bairey O; Lahav M
Medicine (Baltimore); 2010 Sep; 89(5):308-318. PubMed ID: 20827108
[TBL] [Abstract][Full Text] [Related]
4. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
5. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
6. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
Kollmar O; Becker S; Schilling MK; Maurer CA
Transplantation; 2002 Feb; 73(4):669-70. PubMed ID: 11889454
[No Abstract] [Full Text] [Related]
7. Rituximab: therapeutic benefit! Vitamin R?
Mo C; Vire B; Wiestner A
Semin Hematol; 2010 Apr; 47(2):105-6. PubMed ID: 20350656
[No Abstract] [Full Text] [Related]
8. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
[TBL] [Abstract][Full Text] [Related]
9. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
10. [Rituximab and hematological malignancy].
Hatake K; Mishima Y; Terui Y
Nihon Rinsho; 2004 Jul; 62(7):1321-4. PubMed ID: 15283150
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
Coiffier B; Radford J; Bosly A; Martinelli G; Verhoef G; Barca G; Davies A; Decaudin D; Gallop-Evans E; Padmanabhan-Iyer S; Van Eygen K; Wu KL; Gupta IV; Lin TS; Goldstein N; Jewell RC; Winter P; Lisby S;
Br J Haematol; 2013 Nov; 163(3):334-42. PubMed ID: 24032456
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy.
Picardi M; Zeppa P; Ciancia G; Pettinato G; Grimaldi F; Fabbricini R; Mainolfi C; Pane F
Leuk Lymphoma; 2011 Nov; 52(11):2082-9. PubMed ID: 21663508
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-induced hypersensitivity pneumonitis.
Tonelli AR; Lottenberg R; Allan RW; Sriram PS
Respiration; 2009; 78(2):225-9. PubMed ID: 18843175
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.
Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D
Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427
[TBL] [Abstract][Full Text] [Related]
15. Severe pulmonary complications after initial treatment with Rituximab for the Asian-variant of intravascular lymphoma.
Wu SJ; Chou WC; Ko BS; Tien HF
Haematologica; 2007 Jan; 92(1):141-2. PubMed ID: 17229654
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in chronic lymphocytic leukemia.
Jaglowski SM; Byrd JC
Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma.
Gutiérrez A; Rodríguez J; Martínez J; Amezaga R; Ramos R; Galmes B; Bea MD; Ferrer J; Pons J; Sampol A; Morey M; Duran MA; Raurich J; Besalduch J
Leuk Lymphoma; 2006 Jan; 47(1):111-5. PubMed ID: 16321834
[TBL] [Abstract][Full Text] [Related]
18. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.
Quartier P; Tournilhac O; Archimbaud C; Lazaro L; Chaleteix C; Millet P; Peigue-Lafeuille H; Blanche S; Fischer A; Casanova JL; Travade P; Tardieu M
Clin Infect Dis; 2003 Feb; 36(3):e47-9. PubMed ID: 12539090
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
Rao AV; Schmader K
Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
[TBL] [Abstract][Full Text] [Related]
20. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy.
Korte W; Jost C; Cogliatti S; Hess U; Cerny T
Ann Oncol; 1999 Oct; 10(10):1249-50. PubMed ID: 10586345
[No Abstract] [Full Text] [Related]
[Next] [New Search]